A duplexed phenotypic screen for the molecular chaperone heat shock protein 90 and modulators of cellular acetylation

Molecular Cancer Therapeutics

Volumn 6, Issue 3, 2007, Pages 1112-1122

  Hardcastle, Anthea ^a   Tomlin, Peter ^a   Norris, Clair ^a   Richards, Juliet ^a   Cordwell, Matthew ^a   Boxall, Katherine ^a   Rowlands, Martin ^a   Jones, Keith ^a   Collins, Ian ^a   McDonald, Edward ^a   Workman, Paul ^a   Aherne, Wynne ^a  

^a IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1 (3,4,5 TRIMETHOXYPHENYL) 3 PHENYLPROP 2 EN 1 ONE; 2,7 DIMETHYLACRIDINE 3,6 DIAMINE; 4 (BENZO[D]THIAZOL 2 YL) 4 ETHOXYCYCLOHEXA 2,5 DIENONE; 4 [[BIS(2 METHOXYLETHYL)AMINO]SULFONAMIDO] N (6 METHOXYBENZO[D]THIAZOL 2 YL)BENZAMIDE; ADENOSINE TRIPHOSPHATASE; ANTINEOPLASTIC AGENT; CC 000119; CC 000475; CC 002151; CC 002986; CC 003539; CC 003862; CCT 018159; CCT 026194; CCT 030493; CCT 035764; DIMETHYL SULFOXIDE; GELDANAMYCIN; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90 INHIBITOR; HISTONE ACETYLTRANSFERASE; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; TRICHOSTATIN A; TUMOR MARKER; UNCLASSIFIED DRUG;

ACETYLATION; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; COLON CANCER; CONTROLLED STUDY; DRUG DETERMINATION; DRUG MECHANISM; DRUG SCREENING; DRUG STRUCTURE; DRUG TARGETING; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME INHIBITION; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; PHENOTYPE; PRIORITY JOURNAL;

ACETYLATION; ADENOSINE TRIPHOSPHATASES; CELL EXTRACTS; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME INHIBITORS; HCT116 CELLS; HETEROCYCLIC COMPOUNDS, 2-RING; HISTONE ACETYLTRANSFERASES; HISTONE DEACETYLASES; HISTONES; HSP90 HEAT-SHOCK PROTEINS; HUMANS; IMMUNOASSAY; MOLECULAR CHAPERONES; PROTEIN PROCESSING, POST-TRANSLATIONAL;

EID: 34147099104     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-06-0496     Document Type: Article

References (76)

1. Aherne GW, McDonald E, Workman P. Finding the needle in the haystack: why high-throughput screening is good for your health. Breast Cancer Res 2002;4:148-54.
2. Aherne GW, Garrett M, McDonald E, Workman P. Mechanism-based high throughput screening for novel anticancer drug discovery. In: Baguley BC, editor. Anti-cancer drug design. San Diego: Academic Press; 2002. p. 249-67.
3. Johnson PA, Johnson PA. Cellular platforms for HTS: three case studies. Drug Discov Today 2002;7:353-63.
4. Garrett MD, Walton MI, McDonald E, Judson I, Workman P. The contemporary drug development process: advances and challenges in preclinical and clinical development. Prog Cell Cycle Res 2003;5:145-58.
5. Maloney A, Workman P. Hsp90 as a new therapeutic target for cancer therapy: the story unfolds. Expert Opin Biol Ther 2002;2:3-24.
6. Isaacs J, Xu W, Neckers L. Heat shock protein 90 as a molecular target for cancer therapeutics. Cancer Cell 2003;3:213-7.
7. Kelland LR, Sharp SY, Rogers PM, Myers TG, Workman P. DT-Diaphorase expression and tumour cell sensitivity to 17-allylamino, 17-demethoxygeldanamycin, an inhibitor of heat shock protein 90. J Natl Cancer Inst 1999;91:1940-9.
8. Clarke PA, Hostein I, Banerji U, et al. Gene expression profiling of human colon cancer cells following inhibition of signal transduction by 17-allylamino-17-demethoxygeldanamycin, an inhibitor of the Hsp90 molecular chaperone. Oncogene 2000;19:4125-33.
9. Hostein I, Robertson D, DiStefano F, Workman P, Clarke PA. Inhibition of signal transduction by the Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin results in cytostasis and apoptosis. Cancer Res 2001;61: 4003-9.
10. Sharp S, Workman P. Inhibitors of the HSP90 molecular chaperone: current status. Adv Cancer Res 2006;95:323-8.
11. Chiosis G, Rodina A, Moulick K. Emerging hsp90 inhibitors: from discovery to clinic. Anticancer Agents Med Chem 2006;6:1-8.
12. Banerji U, O'Donnell A, Scurr M, et al. Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies. J Clin Oncol 2005;23:4152-61.
13. Vilenchik M, Solit D, Basso A, et al. Targeting wide-range oncogenic transformation via PU24FCI, a specific inhibitor of tumour Hsp90. Chem Biol 2004;11:787-97.
14. Chiosis G, Lucas B, Huezo H, Solit D, Basso A, Rosen N. Development of purine-scaffold small molecule inhibitors of Hsp90. Curr Cancer Drug Targets 2003;3:371-6.
15. Wright L, Barril X, Dymock B, et al. Structure-activity relationships in purine-based inhibitor binding to Hsp90 isoforms. Chem Biol 2004;11: 775-85.
16. Roe SM, Prodromou C, O'Brien R, Ladbury JE, Piper PW, Pearl LH. Structural basis for inhibition of the Hsp90 molecular chaperone by the antitumour antibiotics radicicol and geldanamycin. J Med Chem 1999;42: 260-6.
17. Stebbins CE, Russo AA, Schneider C, Rosen N, Hartl FU, Pavletich NP. Crystal structure of an Hsp90-geldanamycin complex: targeting of a protein chaperone by an antitumour agent. Cell 1997;89:239-50.
18. Rowlands MG, Newbatt YM, Prodromou C, Pearl LH, Workman P, Aherne W. High-throughput screening assay for inhibitors of heat-shock protein 90 ATPase activity. Anal Biochem 2004;327:176-83.
19. Cheung K-M, Matthews T, James K, et al. The identification, synthesis and in vitro biochemical evaluation of a new class of Hsp90 inhibitors. Bioorg Med Chem Lett 2005;15:3338-43.
20. Dymock BW, Barril X, Brough PA, et al. Novel, potent small-molecule inhibitors of the molecular chaperone HSP90 discovered through structure-based design. J Med Chem 2005;48:4212-5.
21. Marcu MG, Neckers LM. The C-Terminal half of heat shock protein 90 represents a second site for pharmacologic intervention in chaperone function. Curr Cancer Drug Targets 2003;3:343-7.
22. Ali MM, Roe SM, Vaughan CK, et al. Crystal structure of an Hsp90-nucleotide-p23/Sba1 closed chaperone complex. Nature 2006;440:1013-7.
23. Yun BG, Huang W, Leach N, Hartson SD, Matts RL. Novobiocin induces a distinct conformation of Hsp90 and alters Hsp90-cochaperone-client interactions. Biochemistry 2004;43:8217-29.
24. Hartson SD, Thulasiraman V, Huang W, Whitesell L, Matts RL. Molybate inhibits Hsp90, induces structural changes in its C-terminal domain, and alters its interactions with substrates. Biochemistry 1999;38: 3837-49.
25. Grammatikakis N, Vultur A, Ramana CV, et al. The role of Hsp90N, a new member of the Hsp90 family, in signal transduction and neoplastic transformation. J Biol Chem 2002;277:8312-20.
26. Chiosis G, Vilenchik M, Kim J, Solit D. Hsp90: the vulnerable chaperone. Drug Discov Today 2004;9:881-8.
27. Panaretou B, Siligardi G, Meyer P. Activation of the ATPase activity of Hsp90 by the stress-related co-chaperone Aha1. Mol Cell 2002;10:1307-18.
28. Freeman BC, Felts SJ, Toft DO, Yamamoto KR. The p23 molecular chaperones act at a late step in intracellular receptor action to differentially affect ligand efficacies. Genes Dev 2000;14:422-34.
29. cdc37. J Biol Chem 2002;277:20151-9.
30. Neckers L. Hsp90 inhibitors as novel cancer chemotherapeutic agents. Trends Mol Med 2002;8:S55-61.
31. de Ruijter JM, van Gennip AH, Caron HN, Kemp S, van Kuilenburg ABP. Histone deacetylases (HDACs): characterisation of the classical HDAC family. Biochem J 2003;370:737-49.
32. Kristeleit R, Stimson L, Workman P, Aherne W. Histone modification enzymes: novel targets for cancer drugs. Expert Opin Emerg Drugs 2004; 9:135-54.
33. Bhalla KN. Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies. J Clin Oncol 2005;23:3971-93.
34. Lindemann RK, Gabrielli B, Johnstone RW. Histone-deacetylase inhibitors for the treatment of cancer. Cell Cycle 2004;3:779-88.
35. Biel M, Wascholowski V, Giannis A. Epigenetics - an epicentre of gene regulation: histones and histone-modifying enzymes. Angew Chem Int 2005;44:3186-3216.
36. Arts J, de Schepper S, Van Emelen K. Histone deacetylase inhibitors: From chomatin remodelling to experimental cancer therapeutics. Curr Med Chem 2003;10:2343-50.
37. Hubbert C, Guardiola A, Shao R, et al. HDAC6 is a microtubule-associated deacetylase. Nature 2002;417:455-8.
38. Haggerty SJ, Koeller KM, Wong JC, Grozinger CM, Schreiber SL. Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation. Proc Natl Acad Sci U S A 2003;100:4389-94.
39. Haggarty SJ, Koeller KM, Wong JC, Butcher RA, Schreiber SL. Multidimensional chemical genetic analysis of diversity-orientated synthesis-derived deacetylase inhibitors using cell-based assays. Chem Biol 2003;10: 383-96.
40. Yu X, Guo S, Marcu MG, et al. Modulation of p53, ErbB1, ErbB2, and Raf1 expression in lung cancer cells by depsipeptide FR901228. J Natl Cancer Inst 2002;94:504-13.
41. Bali P, Pranpat M, Bradner J, et al. Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis of antileukaemia activity of histone deacetylase inhibitors. J Biol Chem 2005;280:26729-34.
42. Kovacs JJ, Murphy PJM, Gaillard S, et al. HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor. Mol Cell 2005;18:601-7.
43. Kouzarides T. Acetylation: a regulatory modification to rival phosphorylation? EMBO J 2000;19:1176-9.
44. Lui L, Scolnick D, Trievel RC. p53 sites acetylated in vitro by PCAF and p300 are acetylated in vivo in response to DNA damage. Mol Cell Biol 1999;19:1202-9.
45. Mahiknecht U, Ottmann OG, Hoeizer D. When the band begins to play: histone acetylation caught in the crossfire of gene control. Mol Carcinog 2000;27:268-71.
46. Timmermann S, Lehrmann H, Polesskays A, Harel-Bellan A. Histone acetylation and disease. Cell Mol Life Sci 2001;58:728-36.
47. Turlais F, Hardcastle A, Rowlands M, et al. High-throughput screening for identification of small molecule inhibitors of histone acetyltransferases using scintillating microplates (FlashPlate). Anal Biochem 2001;298:62-8.
48. Stimson L, Rowlands MG, Newbatt YM, et al. Isothiazolones as inhibitors of PCAF and p300 histone acetyltransferase activity. Mol Cancer Ther 2005;4:1521-32.
49. Stockwell BR, Haggarty SJ, Schreiber SL. High-throughput screening of small molecules in minaturized mammalian cell-based assays involving post-translational modifications. Chem Biol 1996;6:71-83.
50. Mayer TU, Kapoor TM, Haggarty SJ, King RW, Schreiber SL, Mitchison TJ. Small molecule inhibitor of mitotic spindle biopolarity identified in a phenotype-based screen. Science 1999;286:971-4.
51. Hardcastle A, Boxall K, Richards J, et al. Solid phase immunoassays in mechanism-based drug discovery: their application in the development of inhibitors of the molecular chaperone heat-shock protein 90 (Hsp90). Assay Drug Dev Technol 2005;3:273-85.
52. Aherne GW, Rowlands MG, Stimson L, Workman P. Assays for the identification and evaluation of histone acetyltransferese inhibitors. Methods 2002;26:245-53.
53. Barrie SE, Eno-Amooquaye E, Hardcastle A, et al. High-throughput screening for the identification of small-molecule inhibitors of retinoblastoma protein phosphorylation in cells. Anal Biochem 2003;320:66-74.
54. Xu YY, Hemmila I, Mukkala VM, Holttinem S, Lovgren T. Co-fluorescence of europium and samarium in time-resolved fluorimetric immunoassays. Analyst 1991;116:1155-8.
55. Skehan R, Storeng R, Scudiero D, et al. New colourimetric cytotoxicity assay for anti-cancer-drug screening. J Natl Cancer Inst 1990;82:1107-18.
56. Waterborg JH. Dynamics of histone acetylation in Saccharomyces cerevisiae. Biochemistry 2001;40:2599-605.
57. Banerji U, Walton M, Raynaud F, et al. Phamacokinetic-pharmacodynamic relationships for the heat shock protein 90 molecular chaperone inhibitor 17-allylamino, 17-demethoxygeldanamycin in human ovarian cancer xenograft models. Clin Cancer Res 2005;11:7023-32.
58. Sangster TA, Quietsch C, Lindquist S. HSP90 and chromatin. Where is the link? Cell Cycle 2003;2:166-8.
59. Zhao R, Davey M, Shu YC, et al. Navigating the chaperone network: an integrative map of physical and genetic interactions mediated by the HSP90 chaperone. Cell 2005;120:715-27.
60. Maloney A, Clarke PA, Naaby-Hansen S, et al. Gene and protein expression profiling of human ovarian cancer cells treated with the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin (17AAG). Cancer Res 2007. In press.
61. Yoshida M, Hayakawa I, Hayashi N, et al. Synthesis and biological evaluation of benzothiazole derivatives as potent antitumour agents. Bioorg Med Chem Lett 2005;15:3328-32.
62. Ick inhibitor BMS-243117. Bioorg Med Chem Lett 2003; 13:2145-9.
63. Edwards ML, Stemerick DM, Sunkara PS. Chalcones: A new class of antimitotic agents. J Med Chem 1990;33:1948-54.
64. Lawrence NJ, McGown AT, Ducki S, Hadfield JA. The interaction of chalcones with tubulin. Anticancer Drug Des 2000;15:135-41.
65. Meng CQ, Zheng XS, Ni L, et al. Discovery of novel heteroarylsubstituted chalcones as inhibitors of TNF-α-induced VCAM-1 expression. Bioorg Med Chem Lett 2004;14:1513-7.
66. Galigniana MD, Scruggs JL, Herrington J, et al. Heat shock protein 90-dependent (geldanamycin-inhibited) movement of the glucocorticoid receptor through the cytoplasm to the nucleus requires intact cytoskeleton. Mol Endocrinol 2005;12:1903-13.
67. West C, Francis R, Friedman SH. Small molecule/nucleic acid affinity chromatography: application for the identification of telomerase inhibitors which target its key RNA/DNA heteroduplex. Bioorg Med Chem Lett 2001; 11:2727-30.
68. Hannun YA, Bell RM. Aminoacridines, potent inhibitor of protein kinase C. J Biol Chem 1988;263:5124-31.
69. Tamburini BA, Tyler JT. Localized histone acetylation and deacetylation triggered by homologous recombination pathway of double-strand DNA repair. Mol Cell Biol 2005;25:4903-13.
70. Rho JH, Kang D-Y, Park KJ, et al. Doxorubicin induces apoptosis with profile of large-scale DNA fragmentation and without DNA ladder in anaplastic thyroid carcinoma cells via histone hyperacetylation. Int J Oncol 2005;27:465-71.
71. Markham D, Munro S, Soloway J, O'Connor DP, La Thangue NB. DNA-damage-responsive acetylation of pRb regulates binding to E2F-1. EMBO Rep 2006;7:192-8.
72. Wells G, Berry JM, Bradshaw TD, et al. 4-Substituted 4-hydroxycyclohexa-2,5-dien-1-ones with selective activities against colon and renal cancer cell lines. J Med Chem 2003;46:532-41.
73. Pallis M, Bradshaw TD, Westwell AD, Grundy M, Stevens MFG, Russell N. Induction of apoptosis without redox catastrophe by thioredoxin-inhibitory compounds. Biochem Pharmacol 2003;66:1695-705.
74. Chew EH, Matthews CS, Zhang J, et al. Antitumor quinols: role of glutathione in modulating quinol-induced apoptosis and identification of putative cellular protein targets. Biochem Biophys Res Commun 2006;346:242-51.
75. Bradshaw TD, Matthews CS, Cookson J, et al. Elucidation of thioredoxin as a molecular target for antitumour quinols. Cancer Res 2005;65:3911-9.
76. Biel M, Kretsovali A, Karatzali E, Papamatheakis J, Giannis A. Design, synthesis and biological evaluation of a small-molecule inhibitor of the histone acetyltransferase Gcn5. Angew Chem Int 2004;43:3974-6.